Skip to content
City PM
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • DE
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • DE
Thursday 18 March 2021 11:22 am  |  Updated:  Thursday 18 March 2021 12:04 pm

Existing Covid jabs may protect against Brazilian coronavirus mutation, study finds

By: Poppy Wood

Add as a preferred source on Google
NHS England Starts Covid-19 Vaccination Campaign

Existing coronavirus vaccines may prove effective against the Brazilian Covid variant that scientists previously feared would be resistant to antibodies, a University of Oxford study has found.

Researchers studied the impact of natural and vaccine-induced antibodies on different strains of coronavirus. They specifically tested the Astrazeneca and Pfizer/Biontech vaccines on different mutations.

They determined that the Brazil coronavirus variant, also known as the P1 strain or Manaus strain, may be less resistant to antibodies than previously feared.

“These data suggest that natural- and vaccine-induced antibodies can still neutralise these variants, but at lower levels,” it said. “Importantly, the P1 ‘Brazilian’ strain may be less resistant to these antibodies than first feared”.

Professor Gavin Screaton, lead scientist on the study, said: “This study extends our understanding the role of changes in the spike protein in escape from the human immune response, measured as neutralising antibody levels. The results suggest that P1 might be less resistant to vaccine and convalescent immune responses than [the South Africa variant], and similar to [the Kent variant].”

Scientists had previously warned that a potential spread of the Brazil strain may delay the Prime Minister’s roadmap for leaving lockdown.

A member of the government’s Scientific Advisory Group for Emergencies (Sage) said earlier this month that the new strain could force the UK to “go backwards” in terms of relaxing restrictions.

Read more

Molecular Instruments Advances Automated Multiplex Tissue Research with HCR™ Gold IF on the BOND RX Research Staining Instrument

Graham Medley, professor of infectious disease modelling at the London School of Hygiene and Tropical Medicine, said: “It is a variant of concern but we are going to be faced with these in the next six months as we move towards relaxing measures.

“There are going to be challenges on the way – and there is always a risk that we might have to go backwards, and that’s what nobody wants to do is to actually open up and then have to close down again.”

Six cases of the P1 mutation were identified in the UK earlier this month, all from travellers returning to Britain from Brazil. Test and Trace were able to immediately identify five of the cases and ask them to self-isolate.

However, failure to identify the sixth case sparked a nationwide search that lasted more than a week. The missing person was traced back to Croydon on 6 March, where they had been found to be quarantining with their family.

A study published in the New England Journal of Medicine last week found that the Pfizer/Biontech coronavirus vaccine is able to combat the new Brazil variant.

Scientists tested blood samples from patients who had received the Pfizer jab and found it was effective in neutralising a laboratory-made version of the virus similar to the Brazil variant.

Read more

Araris Biotech AG and Taiho Oncology Announce Dosing of First Patient in Phase 1 Trial of ARC-02, a Novel ADC for the Treatment of Non-Hodgkin Lymphoma

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • Coronavirus
  • Vaccine

Trending Articles

  • Harry Styles at Wembley Stadium review: running through the grief

  • Nottingham Forest owner Marinakis announces £210m stadium plans

  • I’ve taken the best train trips in the world. Here are my 5 favourites

  • Natwest boss becomes latest City figure caught in AI social media scam

  • Nothing fails to file accounts months after dissolution threat

More from City PM

  • Molecular Instruments Advances Automated Multiplex Tissue Research with HCR™ Gold IF on the BOND RX Research Staining Instrument

    Business Wire
  • Araris Biotech AG and Taiho Oncology Announce Dosing of First Patient in Phase 1 Trial of ARC-02, a Novel ADC for the Treatment of Non-Hodgkin Lymphoma

    Business Wire
  • Regulator wins decade-long pricing tussle with Pfizer

    Legal
    Hikma reported a jump in profit for 2024
  • Fogo de Chao nominated for Best Casual Dining Toast award

    Toast the City
    Fogo de Chão restaurant exterior with vibrant signage and bustling entrance at popular city location
  • City law firm lands record £36bn BHP case

    Legal
    The Royal Courts of Justice in London, England
  • Government aid ‘worth £28bn’ handed to terrorists, criminals and hostile states

    Politics
    Whitehall and Westminster
  • John Healey’s principles will cost UK defence companies

    Opinion
    Breaking news concept with a digital world map and stock market graphs, illustrating global business trends and data analy...
  • Cruz galloper set for a Winning Ovation in Premier Cup

    Sport
    Audience giving standing ovation at awards ceremony, capturing the excitement and joy of a significant achievement.

City PM — European politics, business and analysis.

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Topics

  • Business
  • Markets
  • AI
  • Technology
  • Opinion
  • Energy

More

  • Politics
  • Economics
  • Fintech
  • Legal
  • Sport
  • Life

Company

  • About City PM
  • Editorial Policy
  • Corrections
  • Contact
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
© 2026 City PM · Published by CityPM Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
About · Editorial Policy · Corrections · Contact · Privacy